Nelarabine

Drug Profile

Nelarabine

Alternative Names: 506U; 506U78; Arranon; Atriance; C 506; Compound 506; GW 506U; GW 506U78; Nelzarabine

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer National Cancer Institute (USA); Novartis
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; T cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma; T cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Jul 2017 No recent reports on development identified - Phase-I/II for Acute lymphoblastic leukaemia and T-cell lymphoma (Combination therapy, Second-line therapy or greater) in Australia, Canada, Austria, France, Italy, Netherlands, United Kingdom and USA (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 04 Jun 2015 Nelarabine is still in phase III development for Acute lymphoblastic leukaemia (Combination therapy, First-line therapy) and T-cell lymphoma (Combination therapy, First-line therapy) in Australia, Canada, New Zealand, Switzerland and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top